Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Ireland Strategy Companies

Merck Sharpe & Dohme begins Irish vaccine facility construction

This article was originally published in Scrip

Executive Summary

Merck Sharp & Dohmehas begun construction of its €200 million vaccine facility in Carlow, Ireland. The facility will create 300 jobs during its 18-month construction, as well as 170 jobs in science, engineering, pharmacy, microbiology and management by its planned opening in 2011. It will be the first stand-alone human vaccine project in Ireland, supporting both recently launched vaccines and future products. It is also supported by the government through the Irish investment agency IDA Ireland.

Table

View full table

Topics

Tags:
Ireland Strategy Companies
Latest Headlines

Supply Chain Derisking: The Case For US-India Partnering Amid China Clout

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

See All
UsernamePublicRestriction

Register

SC020765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By